SAB BIOTHERAPEUTICS INC (SABS) Stock Income Statement
NASDAQ:SABS - Nasdaq - US78397T2024 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 377.80K | 1.32M | 2.24M | 23.90M | 60.88M | |||
| Operating Expenses | 42.46M | 44.13M | 40.21M | 52.70M | 74.27M | |||
| Research and Development | 29.45M | 29.15M | 16.11M | 36.03M | 57.18M | |||
| Selling, General, and Administrative Expenses | 12.71M | 13.98M | 23.80M | 16.38M | 17.09M | |||
| Operating Income | -42.09M | -42.81M | -37.98M | -28.80M | -13.39M | |||
| Interest Income/Expense | 331.90K | 867.60K | 170.00K | -353.00K | -271.00K | |||
| Other Income/Expense | 7.48M | 7.84M | -4.39M | 10.43M | -4.15M | |||
| Non Recurring Items | N/A | N/A | N/A | 0.00 | 666.00K | |||
| Income Before Taxes | -34.28M | -34.11M | -42.19M | -18.71M | -17.14M | |||
| Income Tax | N/A | 0.00 | 0.00 | 26.00K | N/A | |||
| Net Income | -34.28M | -34.11M | -42.19M | -18.74M | -17.14M | |||
| EBITDA | -38.48M | -38.02M | -34.32M | -25.63M | -11.90M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -3.70 | -3.68 | -7.64 | -4.31 | -3.99 | |||
| Non GAAP EPS | -3.70 | -3.74 | -7.28 | -2.70 | N/A | |||
| Statistics | ||||||||
| Profit Margin | -9072.63% | -2579.05% | -1884.50% | -78.40% | -28.16% | |||
| Operating Profit Margin | -11139.49% | -3237.33% | -1696.07% | -120.47% | -22.00% | |||
All data in USD